Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis

World Journal of Gastroenterology

Volumn 21, Issue 45, 2015, Pages 12954-12962

  Hsu, Ping I ^a   Lin, Pei Chin ^b,c   Graham, David Y ^d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Concomitant therapy; Helicobacter pylori; Hybrid therapy; Sequential therapy; Triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL CLEARANCE; DRUG EFFICACY; HELICOBACTER INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; META ANALYSIS; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NON BISMUTH QUADRUPLE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THERAPY; CHI SQUARE DISTRIBUTION; COMBINATION DRUG THERAPY; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIOLOGY; ODDS RATIO; PATHOGENICITY; REMISSION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ODDS RATIO; PROTON PUMP INHIBITORS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84948958352     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i45.12954     Document Type: Review

References (35)

1. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011; 8: 79-88 [PMID: 21293508 DOI: 10. 1038/nrgastro. 2010. 210]
2. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10. 1136/gutjnl-2012-302084]
3. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA; Second Asia-Pacific Conference. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600 [PMID: 19788600 DOI: 10. 1111/j. 1440-1746. 2009. 05982. x]
4. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-1825 [PMID: 17608775]
5. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321-331 [PMID: 18446147 DOI: 10. 1038/ncpgasthep1138]
6. Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacioglu S. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004; 10: 668-671 [PMID: 14991935]
7. De Francesco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O, Stoppino G, Cea U, Pace A, Zotti M, Morini S, Panella C, Ierardi E. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007; 59: 783-785 [PMID: 17329269]
8. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353-1357 [PMID: 17566020]
9. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009; 14: 109-118 [PMID: 19298338 DOI: 10. 1111/ j. 1523-5378. 2009. 00671. x]
10. Hsu PI, Kao SS. Therapy of Helicobacter pylori Infection: Many Drugs for Which Association? In: Manfredi M, de'Angelis GL, editors. Helicobacter pylori. New York: Nova Science Publishers, Inc., 2013: 347-362
11. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16: 139-145 [PMID: 21435092 DOI: 10. 1111/ j. 1523-5378. 2011. 00828. x]
12. Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013; 18: 129-134 [PMID: 23121338 DOI: 10. 1111/hel. 12017]
13. Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, D'Ambrosio P, Castorani L, Bonfrate L, Vannella L, Hassan C, Portincasa P. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013; 37: 647-650 [PMID: 23747131 DOI: 10. 1016/j. clinre. 2013. 04. 003]
14. De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014; 63: 748-752 [PMID: 24586031 DOI: 10. 1099/jmm. 0. 072322-0]
15. Oh DH, Lee DH, Kang KK, Park YS, Shin CM, Kim N, Yoon H, Hwang JH, Jeoung SH, Kim JW, Jang ES, Jung HC. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J Gastroenterol Hepatol 2014; 29: 1171-1176 [PMID: 24955448]
16. Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121-128. e1 [PMID: 23562754 DOI: 10. 1053/j. gastro. 2013. 03. 050]
17. Hsu PI, Wu DC, Tsay, FW. Taiwan Acid Related Disease (TARD) Study Group. Reverse hybrid therapy versus standard triple therapy for Helicobacter pylori infection-A multi-center, randomized, controlled trial. Medicine 2015; in press
18. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17: 3971-3975 [PMID: 22046084 DOI: 10. 3748/wjg. v17. i35. 3971]
19. Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract 2012; 2012: 757926 [PMID: 22778723 DOI: 10. 1155/2012/757926]
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188 [PMID: 3802833]
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748 [PMID: 13655060]
22. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21: 1539-1558 [PMID: 12111919]
23. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-563 [PMID: 17438314]
24. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-186. e3; Discussion e12-13 [PMID: 23751282 DOI: 10. 1016/j. cgh. 2013. 05. 028]
25. Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, Kao SS, Lai KH, Chen A, Tsay FW. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother 2014; 58: 5936-5942 [PMID: 25070099 DOI: 10. 1128/ AAC. 02922-14]
26. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205-213 [PMID: 23158886 DOI: 10. 1016/ S0140-6736(12)61579-7]
27. Wu JY, Hsu PI, Wu DC, Graham DY, Wang WM. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter 2014; 19: 207-213 [PMID: 24612093 DOI: 10. 1111/hel. 12113]
28. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384 [PMID: 15306603]
29. Houben MH, van de Beek D, Hensen EF, de Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-1055 [PMID: 10468680]
30. Gisbert JP, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44: 313-325 [PMID: 20054285 DOI: 10. 1097/MCG. 0b013e3181c8a1a3]
31. Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002; 19: 67-70 [PMID: 11814770]
32. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and metaanalysis of sequential therapy. BMJ 2013; 347: f4587 [PMID: 23926315 DOI: 10. 1136/bmj. f4587]
33. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010; 8: 36-41. e1 [PMID: 19804842 DOI: 10. 1016/j. cgh. 2009. 09. 030]
34. Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter 2011; 16: 146-152 [PMID: 21435093 DOI: 10. 1111/j. 1523-5378. 2011. 00829. x]
35. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011; 34: 604-617 [PMID: 21745241 DOI: 10. 1111/j. 1365-2036. 2011. 04770. x]